Next-generation Alzheimer's treatment study
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new treatment for people with probable Alzheimer's disease. It aims to see if the treatment is safe and effective for patients between 18 and 80 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with probable Alzheimer's disease
- You are between 18 and 80 years old
- You are able to give informed consent
- You do NOT have other neurological disorders (like Parkinson's or stroke)
- You do NOT have bleeding problems or take blood thinners
- You do NOT have serious skin or connective tissue diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.